Moderna's respiratory syncytial virus vaccine candidate for older adults is about 84 percent effective, its phase 3 study showed, and the company said it will seek approval this year.
There are no RSV vaccines, but numerous drugmakers are working toward one, and some have reached promising results, including Pfizer and GSK.
A global study of 37,000 adults aged 60 and older found Moderna's investigative vaccine was 83.7 effective against two or more symptoms of RSV-associated lower respiratory tract disease, and it was 82.4 percent effective against at least three symptoms. No safety concerns were noted, according to Moderna.